No profile photo available

Denitza Blagev, MD

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine

Divisions: Public Health

Board Certification

  • American Board of Internal Medicine (Sub: Critical Care Medicine)
  • American Board of Internal Medicine (Sub: Pulmonary Disease)

Education History

Undergraduate Yale University
 BS
Professional Medical New York University, New York
 MD
Fellowship Harvard Medical School
 Clinical Fellow
Internship/Residency Beth Israel-Deaconess Medical Center
 Intern/Resident
Internship/Residency University of California, San Francisco
 Intern/Resident
Fellowship University of California, San Francisco
 Clinical Fellow
Research Fellow University of California, San Francisco
 Research Fellow
Other Training Institute for Health Care Delivery Research, Intermountain Healthcare
Certification Health Management Academy
 Certification
Certification University of Utah David Eccles School of Business, Intermountain Health
 Certification
Certification Stanford University Graduate School of Business
 Certificate

Selected Publications

Journal Article

  1. Horne BD, Joy EA, Hofmann MG, Gesteland PH, Cannon JB, Lefler JS, Blagev DP, Korgenski EK, Torosyan N, Hansen GI, Kartchner D, Pope CA 3r (2018). Short-Term Elevation of Fine Particulate Matter Air Pollution and Acute Lower Respiratory Infection. American journal of respiratory and critical care medicine, 198(6), 759-766.
  2. Blagev DP, Collingridge DS, Rea S, Press VG, Churpek MM, Carey K, Mularski RA, Zeng S, Arjomandi M (2018). Stability of Frequency of Severe Chronic Obstructive Pulmonary Disease Exacerbations and Health Care Utilization in Clinical Populations. COPD, 5(3), 208-220.
  3. Blagev DP, Callahan SJ, Harris D, Collingridge DS, Hopkins RO, Eve JR, Waddoups L, Aston V, Brown S, Lanspa M (2022). Prospectively Assessed Long-Term Outcomes of Patients with E-Cigarette- or Vaping-associated Lung Injury. Annals of the American Thoracic Society, 19(11), 1892-1899.
  4. Blagev DP, Lanspa M (2020). Autopsy insights from the EVALI epidemic. The Lancet. Respiratory medicine, 8(12), 1165-1166.
  5. Hegewald MJ, Horne BD, Trudo F, Kreindler JL, Chung Y, Rea S, Blagev D (2020). Blood Eosinophil Count and Hospital Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. International journal of chronic obstructive pulmonary disease, 15, 2629-2641.
  6. Blagev DP, Collingridge DS, Rea S, Carey KA, Mularski RA, Zeng S, Arjomandi M, Press V (2020). Laboratory-based Intermountain Validated Exacerbation (LIVE) Score stability in patients with chronic obstructive pulmonary disease. BMJ open respiratory research, 7(1),
  7. Blagev DP, Harris D, Dunn AC, Guidry DW, Grissom CK, Lanspa M (2019). Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study. Lancet (London, England), 394(10214), 2073-2083.
  8. Horne BD, Joy EA, Hofmann MG, Gesteland PH, Cannon JB, Lefler JS, Blagev DP, Korgenski EK, Torosyan N, Hansen GI, Kartchner D, Pope CA 3r (2018). Short-Term Elevation of Fine Particulate Matter Air Pollution and Acute Lower Respiratory Infection. American journal of respiratory and critical care medicine, 198(6), 759-766.
  9. Blagev DP, Collingridge DS, Rea S, Press VG, Churpek MM, Carey K, Mularski RA, Zeng S, Arjomandi (2018). Stability of Frequency of Severe Chronic Obstructive Pulmonary Disease Exacerbations and Health Care Utilization in Clinical Populations. Chronic obstructive pulmonary diseases (Miami, Fla.), 5(3), 208-220.
  10. Blagev DP, Collingridge DS, Rea S, Horne BD, Press VG, Churpek MM, Carey KA, Mularski RA, Zeng S, Arjomandi (2018). The Laboratory-Based Intermountain Validated Exacerbation (LIVE) Score Identifies Chronic Obstructive Pulmonary Disease Patients at High Mortality Risk. Frontiers in medicine, 5, 173.
  11. Stemmer A, Shadmi R, Bregman-Amitai O, Chettrit D, Blagev D, Orlovsky M, Deutsch L, Elnekave (2020). Using machine learning algorithms to review computed tomography scans and assess risk for cardiovascular disease: Retrospective analysis from the National Lung Screening Trial (NLST). PloS one, 15(8), e0236021.
  12. Linares-Perdomo O, Hegewald M, Collingridge DS, Blagev D, Jensen RL, Hankinson J, Morris A (2016). Comparison of NHANES III and ERS/GLI 12 for airway obstruction classification and severity. The European respiratory journal, 48(1), 133-41.

Review

  1. Aberegg SK, Maddock SD, Blagev DP, Callahan S (2020). Diagnosis of EVALI: General Approach and the Role of Bronchoscopy. Chest, 158(2), 820-827.

Editorial

  1. Blagev D (2023). Comparison Among Different Inhalers in COPD: The Differences Are Too Big and Too Small, and It Matters. Chest, 163(4), 731-732.
  2. Callahan SJ, Lanspa MJ, Blagev D (2021). Is COVID-19 masking the ongoing youth vaping crisis?. Expert review of respiratory medicine, 15(9), 1089-1091.
  3. Press VG, Gershon AS, Sciurba FC, Blagev D (2020). Concerns About Coronavirus Disease-Related Collateral Damage for Patients With COPD. Chest, 158(3), 866-868.
  4. Blagev D (2020). Better with Time: Reductions in Mortality in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 17(6), 684-685.
  5. Blagev D (2020). No man is an island: e-cigarette, or vaping, associated lung injury in Europe. The European respiratory journal, 55(2),
  6. Blagev (2015). Evaluation of pulmonary complaints in the emergency department. Time to go back to the basics. Annals of the American Thoracic Society, 12(5), 625-6.

Letter

  1. Lanspa MJ, Blagev DP, Callahan S (2021). Use of e-Cigarettes for Smoking Cessation. JAMA, 325(10), 1006.
  2. Callahan SJ, Harris D, Collingridge DS, Guidry DW, Dean NC, Lanspa MJ, Blagev D (2020). Diagnosing EVALI in the Time of COVID-19. Chest, 158(5), 2034-2037.